Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Deutsches Krebsforschungszentrum patents (2016 archive)


Recent patent applications related to Deutsches Krebsforschungszentrum. Deutsches Krebsforschungszentrum is listed as an Agent/Assignee. Note: Deutsches Krebsforschungszentrum may have other listings under different names/spellings. We're not affiliated with Deutsches Krebsforschungszentrum, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "D" | Deutsches Krebsforschungszentrum-related inventors


Compositions for diagnosis and therapy of diseases associated with aberrant expression of futrins (r-spondins) and/or wnt

The present invention relates to a composition useful for the diagnosis of diseases associated with aberrant expression of the genes encoding the secreted proteins futrin 1, 2, 3 and/or 4(=r-spondin 2, 3, 1 and 4, respectively), e.g. In connection with tumors or diseases of the muscle, kidneys or bones. ... Deutsches Krebsforschungszentrum

Novel promiscuous hpv16-derived t helper epitopes for immunotherapy

The present invention relates to novel amino acid sequences of peptides derived from hpv16 that are able to bind to mhc complexes of class ii, and elicit an immune response. The present invention further relates to pharmaceutical products, such as vaccines and t-cells, based on said epitopes.. ... Deutsches Krebsforschungszentrum

Translation inhibitors in high-dose chemo- and/or high-dose radiotherapy

The present invention relates to an inhibitor of protein translation for use in high-dose chemotherapy and/or high-dose radiotherapy of disease; to an inhibitor of protein translation for use in a combination therapy comprising high-dose chemotherapy and/or high-dose radiotherapy of disease; and to an inhibitor of protein translation for use in preventing adverse effects of high-dose chemotherapy and/or high-dose radiotherapy or for preventing radiation syndrome in a subject. Moreover, the present invention relates to a combined preparation for simultaneous, separate or sequential use comprising at least one inhibitor of protein translation or a pharmaceutically acceptable salt thereof; and at least one chemotherapeutic agent for use in high-dose chemotherapy of disease; to the use of an inhibitor of protein translation in high-dose chemotherapy and/or high-dose radiotherapy of disease; and to a medicament for the therapy of disease which contains (i) at least one inhibitor of protein translation or a pharmaceutically acceptable salt thereof, (ii) at least one chemotherapeutic agent, and (iii) at least one pharmaceutically acceptable carrier. ... Deutsches Krebsforschungszentrum

Immunogenic polypeptides comprising a scaffold polypeptide and a l2 polypeptide or a fragment thereof

The present invention relates to an immunogenic polypeptide comprising a) a scaffold polypeptide, and b) a l2 polypeptide or a fragment of said l2 polypeptide, wherein said scaffold polypeptide constrains the structure of said l2 polypeptide, or of a fragment of said l2 polypeptide. Moreover, the present invention relates to a vaccine comprising said immunogenic polypeptide. ... Deutsches Krebsforschungszentrum

Hcbi sequences as an early marker for the future development of cancer and diseases of the cns and as a target for cancer treatment and prevention

The present invention relates to hcbi (healthy cattle blood isolate) nucleotide sequences as well as probes and primers comprising part of said nucleotide sequences and antibodies against polypeptides encoded by said nucleotide sequences. Said compounds are useful as early markers for the future development of cancer and diseases of the cns.. ... Deutsches Krebsforschungszentrum

Novel means and methods for treating hbv infection and associated conditions

The present invention relates to a polypeptide comprising (a) a first set of six complementarity determining regions (cdrs) configured to bind a first antigen; and (b) (ba) a second set of six cdrs configured to bind a second antigen; or (bb) a ligand capable of binding to a second antigen; wherein (i) said first antigen is selected from hepatitis b virus (hbv) small surface antigen; hbv medium surface antigen; and hbv large surface antigen; and (ii) said second antigen is selected from surface antigens presented by immune effector cells such as natural killer (nk) cells and cytotoxic t lymphocytes (ctls). Also provided are compositions for use in a method of treating or preventing hbv infection and/or a condition caused by said hbv infection, said condition caused by said hbv infection being selected from liver cirrhosis and hepatocellular carcinoma.. ... Deutsches Krebsforschungszentrum

Ttv mirna sequences as an early marker for the future development of cancer and as a target for cancer treatment and prevention

Described are ttv mirnas and probes and primers comprising part of said ttv mirna polynucleic acid. The use of said compounds for diagnosis of cancer or predisposition of cancer is also described.. ... Deutsches Krebsforschungszentrum

Sensitization of cancer cells to apoptosis induction by flavaglines and 5-hydroxy-flavones

The present invention relates to a combined preparation for simultaneous, separate or sequential use comprising at least one flavagline or a pharmaceutically acceptable salt thereof; and/or at least one 5-hydroxy-flavone or a pharmaceutically acceptable salt thereof; and at least one agent activating the intrinsic pathway of apoptosis for use in the treatment of cancer. The n present invention further relates to a medicament comprising the combined preparation of the present invention, as well as to a kit comprising the combined preparation or a medicament according to the present invention and a means for administering at least one of its components. ... Deutsches Krebsforschungszentrum

Modulators of adp-dependent glucokinase (adpgk) and glycerol-3-phosphate dehydrogenase (gpd2) for therapy

Described are compounds capable of modulating (a) the biological activity of adp-dependent glucokinase (adpgk) and/or glycerol-3-phosphate dehydrogenase (gpd2) or (b) the expression of the gene encoding adpgk or gpd2 for use in treating a disease (a) associated with aberrant cell proliferation, e.g., a neoplasm, or (b) of the immune system, e.g., an autoimmune disease.. . ... Deutsches Krebsforschungszentrum

Amatoxin-armed therapeutic cell surface binding components designed for tumour therapy

The invention relates to tumour therapy. In one aspect, the present invention relates to conjugates of a toxin and a target-binding moiety, e.g. ... Deutsches Krebsforschungszentrum

Contour collimator for radiotherapy

The invention relates to a contour collimator for radiotherapy, comprising a plurality of plate-shaped diaphragm elements provided in a guiding block and movably arranged with respect to one another to form a contour diaphragm for a radiation beam emitted by a radiation source towards the collimator, and at least one drive for moving the diaphragm elements, wherein a drive of its own is associated with each diaphragm element, the drives of a group of diaphragm elements are arranged substantially adjacent to one another, and the drive is a linear motor, wherein each linear motor comprises a linearly movable rod directly fixed to the associated diaphragm element. The invention facilitates a design of a contour collimator with a shape being as compact as possible, and wherein both precise and stable adjustability of the diaphragm elements is achieved without a backlash. ... Deutsches Krebsforschungszentrum

Rspondins as modulators of angiogenesis and vasculogenesis

The present invention relates to the use of rspondins, particularly rspondin2 (rspo2) or rspondin3 (rspo3) or rspondin nucleic acids, or regulators or effectors or modulators of rspondin, e.g. Rspo2 and/or rspo3 to promote or inhibit angiogenesis and/or vasculogenesis, respectively. ... Deutsches Krebsforschungszentrum








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Deutsches Krebsforschungszentrum in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Deutsches Krebsforschungszentrum with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###